To include your compound in the COVID-19 Resource Center, submit it here.

FibroGen surges on Phase II pamrevlumab data in IPF

FibroGen Inc. (NASDAQ:FGEN) gained $20.45 (61%) to $53.85 in after-hours trading Monday after it said pamrevlumab (FG-3019) met the primary endpoint

Read the full 215 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE